Teva buys migraine maker

Teva Pharmaceutical Industries (TEVA -0.7%) acquires Labrys Biologics for as much as $825M ($200M upfront and up to $625M in milestone payments). Labrys's lead product is LBR-101, an anti-CGRP mAb for the prevention of chronic and high frequency episodic migraines. Peak sales of the product could hit $2B - 3B. It is currently in a Phase 2b clinical trial.

From other sites
Comments (2)
  • hldemfldem
    , contributor
    Comments (18) | Send Message
    Hope this will increase per share profits, and dividends??
    3 Jun 2014, 07:15 PM Reply Like
  • stockade
    , contributor
    Comments (18) | Send Message
    Been a long time holder of teva going back to Barr and keep waiting for another value run on this stock
    5 Jun 2014, 02:36 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs